A Randomized, Placebo-Controlled, Pilot Crossover Study to Evaluate the Effect of Amifampridine Phosphate (3,4-Diaminopyridine Phosphate) in Patients with MuSK Antibody Positive Myasthenia Gravis

Trial Profile

A Randomized, Placebo-Controlled, Pilot Crossover Study to Evaluate the Effect of Amifampridine Phosphate (3,4-Diaminopyridine Phosphate) in Patients with MuSK Antibody Positive Myasthenia Gravis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Amifampridine (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2017 Results from this trial will be presented at the International Conference on Myasthenia Gravis and Related Disorders, according to a Catalyst Pharmaceuticals media release.
    • 29 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top